3,552 results match your criteria Prolactinoma


Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.

Horm Cancer 2019 Apr 18. Epub 2019 Apr 18.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Natural course of prolactinomas after menopause is not fully elucidated. The aim of this study was to compare recurrence rate after cabergoline withdrawal in premenopausal vs. postmenopausal women with microprolactinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-019-00363-4DOI Listing

Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?

Geburtshilfe Frauenheilkd 2019 Apr 6;79(4):365-374. Epub 2019 Mar 6.

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany.

The diagnosis and treatment of pituitary disease in pregnancy represents a special clinical challenge. Not least because there is very little data on the treatment of pregnant patients with pituitary disorders. A selective search of the literature was carried out with the aim of compiling evidence about the diagnosis and treatment of pituitary disease in pregnancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0794-7587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461462PMC
April 2019
1 Read

Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.

Cell Death Dis 2019 Apr 18;10(5):335. Epub 2019 Apr 18.

Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, 305 East Zhongshan Road, 210002, Nanjing, China.

The treatment of hyperprolactinemia is based on the use of dopamine agonists, mainly bromocriptine (BRC) and cabergoline (CAB). They reduce tumour size effectively and restore gonadal function. However, there is a difference in drug sensitivity between CAB and BRC in patients with prolactinoma, although the underlying mechanisms are still unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1526-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472389PMC

[Pituitary adenomas].

Nervenarzt 2019 Apr 17. Epub 2019 Apr 17.

Klinik für Neurochirurgie, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland.

Despite characteristic symptoms the diagnosis of clinically relevant pituitary adenomas is often delayed until an advanced stage due to the rarity of the disease. The typical clinical manifestations are presented in this review article. The recent discovery of the USP8 mutation in Cushing's disease and of X‑linked acrogigantism (X-LAG) syndrome in early onset gigantism were milestones in the search for the molecular etiology of pituitary adenomas. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00115-019-0708-4
Publisher Site
http://dx.doi.org/10.1007/s00115-019-0708-4DOI Listing
April 2019
2 Reads

MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.

Endocr Pract 2019 Apr;25(4):340-352

To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and no visible tumor at follow-up, respectively. Giant prolactinoma (median size, 4. Read More

View Article

Download full-text PDF

Source
http://journals.aace.com/doi/10.4158/EP-2018-0392
Publisher Site
http://dx.doi.org/10.4158/EP-2018-0392DOI Listing
April 2019
2 Reads

SUCCESSFUL TREATMENT OF A PROLACTINOMA (CASE REPORT).

Georgian Med News 2019 Feb(287):26-29

I. Horbachevsky Ternopil State Medical University, Ukraine.

Currently, lots of young couples are facing infertility. One of the relatively rare causes of female infertility is prolactinoma - hormonally active pituitary tumor that secretes excessive quantity of prolactin. Excessive prolactin production is leading to anovulation and women infertility. Read More

View Article

Download full-text PDF

Source
February 2019
1 Read

miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.

Brain Res Bull 2019 Apr 1. Epub 2019 Apr 1.

Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address:

Prolactinoma is a common subtype of pituitary tumors. Dopamine receptor agonists are the preferred treatment for prolactinoma; however, with this therapy, drug resistance often occurs. In our previous work, we found that partial resistant prolactinomas showed increased fibrosis and that the transforming growth factor (TGF)-β1/Smad3 signaling pathway mediated fibrosis and was involved in drug resistance. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03619230183101
Publisher Site
http://dx.doi.org/10.1016/j.brainresbull.2019.03.013DOI Listing
April 2019
4 Reads

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience.

Endocr Connect 2019 Apr 1. Epub 2019 Apr 1.

S Cannavo, Endocrine Unit of University Hospital "AOU Policlinico G. Martino", PhD School of Clinical and Experimental Biomedical Sciences, Department of Human Pathology "G. Barresi", Universita degli Studi di Messina, Messina, Italy.

In aggressive pituitary tumours (PT) showing local invasion or growth/recurrence despite multimodal conventional treatment, temozolomide (TMZ) is considered a further therapeutic option, while little data is available on peptide receptor radionuclide therapy (PRRT). We analysed PRRT effectiveness, safety and long-term outcome in three patients with aggressive PT, also reviewing the current literature. Patient #1 (F, giant prolactinoma) received 5 cycles (total dose 37 GBq) of 111In-DTPA-octreotide over 23 months, after unsuccessful surgery and long-term dopamine-agonist treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-19-0065DOI Listing
April 2019
2 Reads

Outcomes of Surgical Repair of Skull Base Defects Following Endonasal Pituitary Surgery: A Retrospective Observational Study.

Indian J Otolaryngol Head Neck Surg 2019 Mar 15;71(1):66-70. Epub 2018 Oct 15.

1Department of ENT, Head and Neck Surgery, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu 600116 India.

Skull base defects following endonasal surgery for pituitary macroadenoma need to be addressed during the surgery to prevent serious postoperative complications like cerebrospinal fluid (CSF) leak. The objective of this study is to assess the incidence of CSF leak following pituitary surgery and the methods of effective skull base repair. This is a retrospective observational study conducted in a tertiary care hospital after obtaining due clearance from the Institutional ethics committee. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12070-018-1511-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401034PMC
March 2019
1 Read

The Intriguing Case of a Double Pituitary Adenoma.

World Neurosurg 2019 Mar 18. Epub 2019 Mar 18.

Department of Medicine Division of Endocrinology, Emory University School of Medicine, Atlanta, GA; Department of Neurological Surgery, Emory University School of Medicine, Atlanta, GA. Electronic address:

Background: When distinct pituitary hypersecretory manifestations coexist, the differential diagnosis includes plurihormonal or double pituitary adenomas. We describe a rare case of hypercortisolemia and hyperprolactinemia caused by two non-contiguous adenomas that required two surgeries.

Case Presentation: A 37-year-old woman presented with 6-month of weight gain, amenorrhea, joint pain, leg swelling and skin changes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.02.242DOI Listing
March 2019
3 Reads

Ectopic pituitary adenomas: common presentations of a rare entity.

Pituitary 2019 Mar 20. Epub 2019 Mar 20.

Department of Radiology, Mayo Clinic, 4500 San Pablo Road S, Jacksonville, FL, 32224, USA.

Purpose: Ectopic pituitary adenomas (EPA) are rare tumors thought to arise from embryological remnants along the route of normal pituitary migration. Clinically, these tumors vary in hormonal activity and can exert mass effect based on location and size.

Methods: We performed a single-center retrospective analysis of patients with diagnosis of ectopic pituitary adenoma from 2001 to 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11102-019-00954-yDOI Listing
March 2019
3 Reads

THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.

Endocr Pract 2019 Mar 13. Epub 2019 Mar 13.

Department of Neuro-Endocrinology in Clinical Neurological Surgery, Weill Cornell Medicine, NY 10065.

Objectives To evaluate the effect of raloxifene on prolactin levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Methods We conducted a retrospective chart review of 14 patients with prolactinoma on stable dose of DA for 6 months who received raloxifene 60 mg daily as Prolactin (PRL) could not be normalized despite being on fairly high doses of DA. Patients were informed that raloxifene is not FDA approved for prolactinoma treatment. Read More

View Article

Download full-text PDF

Source
http://journals.aace.com/doi/10.4158/EP-2018-0321
Publisher Site
http://dx.doi.org/10.4158/EP-2018-0321DOI Listing
March 2019
4 Reads

mPRs represent a novel target for PRL inhibition in experimental prolactinomas.

Endocr Relat Cancer 2019 Mar 1. Epub 2019 Mar 1.

G Diaz-Torga, Lab Fisiopatologia Hormonal, IBYME- CONICET, CABA, BUenos Aires, C1428ADN, Argentina.

Membrane progesterone receptors are known to mediate rapid nongenomic progesterone effects in different cell types. Recent evidence revealed that mPRα is highly expressed in the rat pituitary, being primarily localized in lactotrophs, acting as an intermediary of P4-inhibitory actions on prolactin secretion. The role of mPRs in prolactinoma development remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-18-0409DOI Listing
March 2019
1 Read

Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study.

J Clin Endocrinol Metab 2019 Mar 8. Epub 2019 Mar 8.

Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Istanbul, TURKEY.

Context: Dopamine agonist (DA)-induced impulse control disorder (ICD) in prolactinomas is not sufficiently known.

Objective: To evaluate the prevalence of DA-induced ICDs and possible risk factors related to these disorders in patients with prolactinoma.

Design, Setting And Participants: This is a cross-sectional multicenter study involving 308 prolactinoma patients followed-up in tertiary referral centers who received at least 3 months of DA therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02202DOI Listing
March 2019
2 Reads

Pituitary carcinomas: review of the current literature and report of atypical case.

Br J Neurosurg 2019 Mar 5:1-6. Epub 2019 Mar 5.

a Department of Neurological Surgery, Wexner Medical Center , The Ohio State University College of Medicine , Columbus , OH , USA.

Introduction: Pituitary carcinomas are poorly understood, rare entities. They are distinguished from adenomas not by histopathological features but rather by the presence of metastases.

Objective: We discuss the diagnosis, mechanism of dissemination and pathogenesis based on a review of the literature and illustrated by a singular case. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2019.1582750DOI Listing
March 2019
1 Read

Clinical utility of routine postoperative morning cortisol monitoring in detecting new hypothalamic-pituitary-adrenal axis insufficiency following endoscopic transsphenoidal surgery for sellar lesions.

J Neurosurg 2019 Mar 1:1-5. Epub 2019 Mar 1.

1Department of Neurological Surgery and.

OBJECTIVEHypothalamic-pituitary-adrenal (HPA) axis dysfunction is a well-documented complication of transsphenoidal craniotomy (TSC) for sellar lesions. The authors aimed to assess their multidisciplinary approach to the diagnosis and treatment of postoperative hypocortisolemia utilizing conservative screening methods.METHODSThe authors performed a retrospective review of 257 patients who underwent TSC for pituitary adenoma (PA) or Rathke cleft cyst (RCC) at the University of Southern California between 2012 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3171/2018.11.JNS182521DOI Listing
March 2019
4 Reads

AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center.

Endocr Connect 2019 Mar 1. Epub 2019 Mar 1.

A Soto, Division of Endocrinology, Virgen del Rocio University Hospital, Sevilla, Spain.

Background: Pituitary adenomas have a high disease burden due to tumor growth/invasion and disordered hormonal secretion. Germline mutations in genes such as MEN1 and AIP are associated with early onset of aggressive pituitary adenomas that can be resistant to medical therapy.

Aims: We performed a retrospective screening study using published risk criteria to assess the frequency of AIP and MEN1 mutations in pituitary adenoma patients in a tertiary-referral center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-19-0027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432872PMC
March 2019
5 Reads

Different cabergoline effect on metabolic and anthropometric parameters in female prolactinoma patients versus idiopathic hyperprolactinemia patients.

Endocr Metab Immune Disord Drug Targets 2019 Feb 18. Epub 2019 Feb 18.

Microbiology at specialized medical hospital, Mansoura University, Mansoura. Egypt.

Objective: We aimed in the current study to: 1) evaluate and compare metabolic and anthropometric profile in female patients with newly diagnosed prolactin secreting adenoma versus female idiopathic hyperprolactinemic patients 2) compare the effects of one year cabergoline therapy on the metabolic profile and anthropometric parameters (by using visceral adiposity index as index for evaluation of adipose tissue dysfunction) in female patients with prolactin secreting pituitary adenoma to female idiopathic hyperprolactinemic patients.

Patients And Methods: We enrolled 40 female patients with newly diagnosed prolactin-secreting pituitary adenoma (29 patients with micro adenoma and 11 patients with macro adenoma) and 40 female patients with idiopathic hyperprolactinemia, who were matched according to: age; weight; BMI; waist; and prolactin levels. The participants were enrolled in this study at the time of diagnosis before therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1871530319666190219103812DOI Listing
February 2019
1 Read

Increased androgen secretion in patients with prolactinomas: the impact of altered HPA function.

Pituitary 2019 Apr;22(2):170-178

Division of Clinical and Molecular Endocrinology, UH Cleveland Medical Center and Case Western University, 11100 Euclid Avenue, Cleveland, OH, 44106, USA.

Background And Objectives: Earlier studies suggested that hyperprolactinemia was associated with elevated serum DHEA-S levels. The importance of DHEA-S measurements in the diagnosis of adrenal insufficiency prompted us to assess adrenal androgen levels in hyperprolactinemic subjects with normal or impaired function.

Methods: Prospective study including 122 medically treated and 26 surgically patients with prolactinomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11102-019-00948-wDOI Listing
April 2019
5 Reads

Long-term therapeutic success with multimodal therapy in aggressive prolactinoma.

Endocrinol Diabetes Nutr 2019 Feb 20. Epub 2019 Feb 20.

Department of Endocrinology, Hospital Universitario Ramón y Cajal y Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.endinu.2019.01.002DOI Listing
February 2019

[Differential diagnosis and treatment of pituitary adenomas].

HNO 2019 Apr;67(4):307-318

Klinik für Neurochirurgie, Universität Ulm, Albert-Einstein-Allee 23, 89075, Ulm, Deutschland.

Pituitary adenomas are among the most common primary brain tumors. These tumors can produce all hormones of the anterior pituitary and thus cause endocrine diseases. Compression of the pituitary gland, the surrounding cranial nerves, or brain structures can lead to hypopituitarism, cranial nerve deficits, or diverse neurological symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00106-019-0629-3DOI Listing
April 2019
2 Reads

Glioblastoma and prolactinoma: a rare simultaneous occurrence.

J Surg Case Rep 2019 Feb 8;2019(2):rjz030. Epub 2019 Feb 8.

Department of Neurosurgery, King Abdualziz Medical City, Riyadh, Saudi Arabia.

The simultaneous development of two or more primary central nervous system (CNS) tumors of different cell types represents 0.9% of all diagnosed CNS tumors. To the best of our knowledge, the simultaneous occurrence of glioblastoma and pituitary adenomas has been reported four times in the English literature, with only two cases harboring prolactinoma and glioblastoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jscr/rjz030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368138PMC
February 2019
3 Reads

Prolactin and alteration of fertility.

Ceska Gynekol Winter 2018;83(3):232-235

Aim: Physiology and pathology of prolactin production, clinical consequences.

Design: Review.

Setting: Reprogenesis International, Brno. Read More

View Article

Download full-text PDF

Source
February 2019
9 Reads

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas.

Front Endocrinol (Lausanne) 2018 22;9:768. Epub 2019 Jan 22.

Department of Neurosurgery, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China.

Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are even conflicting conclusions. The main aim of this paper is to review the different pathways of dopamine and its agonists in prolactinomas to help to gain a better understanding of their functions and drug resistance mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357924PMC
January 2019
2 Reads

Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old.

Medicine (Baltimore) 2019 Feb;98(6):e14380

Department of Neurosurgery, Peking Union Medical College Hospital, Peking Union Medical College.

Prolactinoma is one of the most common pituitary tumors, but relatively uncommon in patients under 14 years old. Surgery is the second-line treatment for prolactinoma when patients show resistance or intolerance to medical therapy. There are only a few published series of children who underwent surgery treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014380DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380812PMC
February 2019
3 Reads
5.723 Impact Factor

Epidemiology and Management Challenges in Prolactinomas.

Neuroendocrinology 2019 Feb 7. Epub 2019 Feb 7.

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, Liège Université, Liège, Belgium,

Clinically relevant pituitary adenomas are present in about 1 per 1,000 of the general population and prolactinomas are by far the most common clinical subtype of pituitary adenomas. Usually prolactinomas affect premenopausal women and present with typical symptoms of menstrual disturbance and/or galactorrhea. They are generally managed with dopamine agonists to restore fertility and to control symptoms and tumor size. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497746DOI Listing
February 2019
2 Reads

[Clinical and functional characteristics of giant pituitary adenomas in the population of patients in the Moscow region].

Zh Vopr Neirokhir Im N N Burdenko 2018;82(6):76-81

Moscow Regional Researh and Clinical Institute, Moscow, Russia.

Benign pituitary tumors are the most common sellar neoplasms. Lesions larger than 39 mm in the maximum dimension are called giant. They are rare, and, therefore, there are few data on the clinical and morphological features of giant pituitary tumors with different hormonal activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/neiro20188206176DOI Listing
January 2018
2 Reads

Metabolomics-A Promising Approach to Pituitary Adenomas.

Front Endocrinol (Lausanne) 2018 17;9:814. Epub 2019 Jan 17.

6th Department of Medical Sciences, Department of Endocrinology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Metabolomics-the novel science that evaluates the multitude of low-molecular-weight metabolites in a biological system, provides new data on pathogenic mechanisms of diseases, including endocrine tumors. Although development of metabolomic profiling in pituitary disorders is at an early stage, it seems to be a promising approach in the near future in identifying specific disease biomarkers and understanding cellular signaling networks. To review the metabolomic profile and the contributions of metabolomics in pituitary adenomas (PA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00814DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345099PMC
January 2019
9 Reads

[Unilateral visual loss revealing nercotic prolactinoma].

J Fr Ophtalmol 2019 Feb 22;42(2):e79-e82. Epub 2019 Jan 22.

Service d'ophtalmologie, Hôpital militaire d'instruction Mohammed V, Faculté de médecine et de pharmacie, université Mohammed V-Rabat-Maroc, Rabat Maroc.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jfo.2018.05.013DOI Listing
February 2019
1 Read

Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report.

J Med Case Rep 2019 Jan 20;13(1):18. Epub 2019 Jan 20.

Department of Neurosurgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

Background: Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.

Case Presentation: A 27-year-old Japanese man presented to our institution with a history of visual disturbance for 1 year and general fatigue for 3 months. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1939-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6339691PMC
January 2019
14 Reads

Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China.

Pituitary 2019 Apr;22(2):113-123

Department of Endocrinology, Peking Union Medical College Hospital, Beijing, 100730, China.

Purpose: To explore the clinical characteristics of pituitary adenomas in patients with MEN1 and to summarize treatment strategies for MEN1 in a Chinese population.

Methods: We retrospectively analyzed 54 MEN1 patients with pituitary adenomas diagnosed at Peking Union Medical College Hospital from March 2003 to January 2017. Clinical data, laboratory testing results, treatments of involved glands and treatment responses were collected and analyzed. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11102-019-00939-x
Publisher Site
http://dx.doi.org/10.1007/s11102-019-00939-xDOI Listing
April 2019
23 Reads
2.222 Impact Factor

Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.

J Clin Endocrinol Metab 2019 Jun;104(6):1929-1936

Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

Context: Aggressive prolactin (PRL)-secreting pituitary adenomas that are resistant to conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic challenge. The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved to treat neuroendocrine tumors (NETs), and cotreatment with the somatostatin receptor ligand octreotide improved median progression-free survival in patients with metastatic pancreatic NETs.

Patient, Intervention, And Results: We describe off-label everolimus treatment of a prolactinoma (PRLoma) refractory to cabergoline, repeat surgical resection, and radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/jc.2018-02461DOI Listing
June 2019
5 Reads

Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.

Pathol Oncol Res 2019 Jan 8. Epub 2019 Jan 8.

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Rapid advance in oncology leads to increasing survival of oncologic patients. More and more of them live long enough to reach either the natural age of menopause or, as a side effect of their oncotherapy, experience the cessation of gonadal function, leading to premature ovarian insufficiency, with disturbing vasomotor symtoms and long-term negative cardiovascular and skeletal effects. Thus, an ever increasing number of cancer survivors search endocrinologic help in the form of hormone replacement therapy (HRT). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12253-018-00569-x
Publisher Site
http://dx.doi.org/10.1007/s12253-018-00569-xDOI Listing
January 2019
13 Reads

PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.

Biomed Pharmacother 2019 Mar 3;111:638-648. Epub 2019 Jan 3.

Multidisciplinary Center for Pituitary Adenomas of Chongqing, Department of Neurosurgery, Xinqiao Hospital, Army Medical University, 183th Street of Shapingba District, Chongqing, 400037, China. Electronic address:

Bromocriptine, the most commonly used dopamine (DA) receptor agonists for prolactinoma, can effectively reduce tumor size of prolactinoma, but the mechanism was not fully understood. Apoptosis had been well-recognized to contribute to the tumor mass regression caused by bromocriptine. However, whether other types of non-apoptotic cell death involved in the bromocriptine-induced prolactinoma shrinkage had not been fully clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2018.12.128DOI Listing
March 2019
4 Reads

Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas.

Clin Endocrinol (Oxf) 2019 Mar 15;90(3):457-467. Epub 2019 Jan 15.

Neuroendocrinology Clinic, Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.

Objective: To evaluate the quality of life (QoL) in patients with pituitary adenomas in comparison with healthy Mexican population QoL scores.

Design & Measurements: Cross-sectional study using the short form 36 questionnaire (SF-36) in 175 patients with pituitary adenomas grouped by adenoma subtype and disease activity, and compared them with the healthy Mexican population normative QoL scores.

Patients: A total of 44 patients with non-functioning pituitary adenomas (NFPA), 48 with acromegaly, 53 with prolactinomas and 30 with Cushing disease (CD) were enrolled in this study. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13915
Publisher Site
http://dx.doi.org/10.1111/cen.13915DOI Listing
March 2019
5 Reads

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases.

Front Endocrinol (Lausanne) 2018 13;9:625. Epub 2018 Nov 13.

Endocrinology Service, Brasilia University Hospital, Brasília, Brazil.

Prolactinomas are preferentially treated with dopamine agonists. However, a few adenomas are resistant to this treatment. To evaluate the characteristics of patients with resistance to dopamine agonists in the long-term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2018.00625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277870PMC
November 2018
1 Read

Fertility after transsphenoidal surgery in patients with prolactinomas: A meta-analysis.

Clin Neurol Neurosurg 2019 Jan 1;176:53-60. Epub 2018 Dec 1.

Computational Neuroscience Outcomes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; School of Pharmacy, MCPHS University, Boston, MA, USA(3). Electronic address:

Pituitary prolactinomas in women often lead to amenorrhea, galactorrhea, or infertility. The purpose of this study was to evaluate the effectiveness of transsphenoidal surgery (TSS) in restoring fertility in women with proloactinomas. A systematic search of the literature was conducted in accordance with PRISMA guidelines through 6/13/2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clineuro.2018.11.024DOI Listing
January 2019
3 Reads
1.248 Impact Factor

Giant prolactinoma, germline BRCA1 mutation, and depression: a case report.

J Med Case Rep 2018 Dec 6;12(1):360. Epub 2018 Dec 6.

Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário de São João, E.P.E., Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal.

Background: Giant prolactinomas are very rare pituitary tumors that may exhibit an aggressive behavior and present with a life-threatening condition.

Case Presentation: A 25-year-old white woman was admitted to our hospital with a headache, psychomotor retardation, reduced vision, and loss of autonomy in daily activities. Her past medical history was significant for having oligomenorrhea and a depressive syndrome since her mother's death. Read More

View Article

Download full-text PDF

Source
https://jmedicalcasereports.biomedcentral.com/articles/10.11
Publisher Site
http://dx.doi.org/10.1186/s13256-018-1890-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282289PMC
December 2018
21 Reads

Management of Dopamine Agonist-Resistant Prolactinoma.

Authors:
Dominique Maiter

Neuroendocrinology 2019 Mar 18:1-9. Epub 2019 Mar 18.

Division of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium,

Dopamine agonists are usually very effective in the treatment of prolactinomas. Nonetheless, a subset of individuals does not respond satisfactorily to these agents, and this resistance is characterized by failure to achieve normoprolactinemia and a 30% or more reduction in maximal tumor diameter (in the case of macroprolactinoma) under maximally tolerated doses. The overall prevalence of dopamine agonist resistance is 20-30% for bromocriptine (BRC) and around 10% for cabergoline (CAB). Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/495775
Publisher Site
http://dx.doi.org/10.1159/000495775DOI Listing
March 2019
13 Reads

Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid Aneurysm Embedded Within a Prolactinoma After Cabergoline Administration.

World Neurosurg 2019 Feb 19;122:495-499. Epub 2018 Nov 19.

Department of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

Background: A small number of reports have described subarachnoid hemorrhage resulting from a ruptured aneurysm embedded within a prolactinoma. To the best of our knowledge, no reports have described an embedded carotid cavernous fistula. We report a patient with carotid cavernous fistula secondary to a ruptured internal carotid artery aneurysm embedded within a prolactinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.11.071DOI Listing
February 2019
13 Reads

Human Prolactinoma: A View of Protein-Protein Interaction Pattern.

Int J Endocrinol Metab 2018 Oct 6;16(4):e67332. Epub 2018 Aug 6.

Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

The aim of this study was to identify the highly expressed genes in terms of interaction concept in Prolactinoma. The study was conducted by additional analysis of the available data from the GEO database. The online tool, GEO2R, was used to analyze the gene expression profile of GSE36314 dataset using the GPL8300 platform. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5812/ijem.67332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216114PMC
October 2018
2 Reads

Screening of AIP Gene Variations in a Cohort of Turkish Patients with Young-Onset Sporadic Hormone-Secreting Pituitary Adenomas.

Genet Test Mol Biomarkers 2018 Nov 21. Epub 2018 Nov 21.

2 Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University , Istanbul, Turkey .

Aims: Aryl hydrocarbon receptor-interacting protein (AIP) gene mutations have long been associated with apparently sporadic pituitary adenomas (PAs) with a prevalence range of 0-12%. The aim of this study was to evaluate the frequency of germline AIP variations in a large cohort of apparently sporadic PAs diagnosed before the age of 40 years, who did not exhibit hypercalcemia and/or MEN1 syndrome components during long-term follow-up.

Materials And Methods: A total of 97 patients, diagnosed with functional PAs ≤40 years old, composed of somatotropinoma (n = 55), prolactinoma (n = 25), and corticotrophinoma (n = 17), were recruited for this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/gtmb.2018.0133DOI Listing
November 2018
15 Reads

Spontaneous preoperative pituitary adenoma resolution following apoplexy: a case presentation and literature review.

Br J Neurosurg 2018 Nov 19:1-6. Epub 2018 Nov 19.

a Department of Neurological Surgery , University of Miami Miller School of Medicine , Miami , FL , USA.

Purpose: We aim to more fully understand the incidence and natural history of spontaneously resolving non-functioning pituitary adenomas (NFPAs).

Methods: We report a case of spontaneous complete resolution of a NFPA revealed by preoperative magnetic resonance imaging. In addition, we searched all major databases and neurosurgery journals to perform a comprehensive literature review of all previously reported cases of spontaneously resolving NFPAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02688697.2018.1529737DOI Listing
November 2018
3 Reads

Association of prolactin receptor (PRLR) variants with prolactinomas.

Hum Mol Genet 2018 Nov 15. Epub 2018 Nov 15.

Academic Endocrine Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LJ, UK.

Prolactinomas are the most frequent type of pituitary tumors, which represent 10-20% of all intracranial neoplasms in humans. Prolactinomas develop in mice lacking the prolactin receptor (PRLR), which is a member of the cytokine receptor superfamily that signals via Janus kinase-2-signal transducer and activator of transcription-5 (JAK2-STAT5) or phosphoinositide 3-kinase-Akt (PI3K-Akt) pathways to mediate changes in transcription, differentiation and proliferation. To elucidate the role of the PRLR gene in human prolactinomas, we determined the PRLR sequence in 50 DNA samples (35 leucocyte, 15 tumors) from 46 prolactinoma patients (59% males, 41% females). Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg
Publisher Site
http://dx.doi.org/10.1093/hmg/ddy396DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400049PMC
November 2018
15 Reads

Controversies in Breastfeeding.

Authors:
Riccardo Davanzo

Front Pediatr 2018 1;6:278. Epub 2018 Nov 1.

Division of Pediatrics and Neonatology, Department of Mother and Child Health, Ospedale Madonna delle Grazie, Matera, Italy.

When addressing the compatibility of breastfeeding with certain maternal conditions, we need to differentiate between "contraindication" and "obstacle." Failure to distinguish between the two confuses new mothers and their families, and engenders misconceptions about breastfeeding advice by health professionals. Health conditions that may simply impede the initiation and duration of breastfeeding are often wrongly referred to as true contraindications to breastfeed, under the assumption that they might harm the health of the mother and/or that of the nursing infant. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fped.2018.00278/
Publisher Site
http://dx.doi.org/10.3389/fped.2018.00278DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221984PMC
November 2018
21 Reads

Retrospective analysis of 52 patients with prolactinomas following endoscopic endonasal transsphenoidal surgery.

Medicine (Baltimore) 2018 Nov;97(45):e13198

Department of Neurosurgery, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi.

Background: Prolactinomas affect patients' quality of life and even endanger lives. The study aimed to investigate the effect of the endoscopic endonasal transsphenoidal approach (EETA) on 52 patients with prolactinomas.

Methods: A total of 52 patients with prolactinomas who had previously undergone EETA in the People's Hospital of Xinjiang Uygur Autonomous Region between January 2013 and December 2017 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000013198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250442PMC
November 2018
11 Reads

Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.

Eur J Endocrinol 2019 Jan;180(1):31-40

Division of Endocrinology, Gerontology and Metabolism, Department of Medicine and Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.

Background Dopamine agonists (DAs) are the main treatment for patients with hyperprolactinemia and prolactinomas. Recently, an increasing number of reports emphasized DAs' psychological side effects, either de novo or as exacerbations of prior psychiatric disease. Methods Review of prospective and retrospective studies (PubMed 1976, September 2018) evaluating the psychological profile of DA-treated patients with hyperprolactinemia and prolactinomas. Read More

View Article

Download full-text PDF

Source
https://eje.bioscientifica.com/view/journals/eje/aop/eje-18-
Publisher Site
http://dx.doi.org/10.1530/EJE-18-0682DOI Listing
January 2019
13 Reads

The ERα membrane pool modulates the proliferation of pituitary tumours.

J Endocrinol 2018 Nov 1. Epub 2018 Nov 1.

A Torres, Centro de Microscopía Electrónica, Universidad Nacional de Córdoba, Facultad de Ciencias Médicas, - Consejo Nacional de Investigaciones Científicas Técnicas (CONICET) Instituto de Investigaciones en Ciencias de la Salud, Córdoba, Argentina.

The molecular mechanisms underlying the ERα nuclear/cytoplasmic pool that modulates pituitary cell proliferation have been widely described, but it is still not clear how ERα is targeted to the plasma membrane. The aim of this study was to analyse ERα palmitoylation and the plasma membrane ERα (mERα) pool, and their participation in E2-triggered membrane-initiated signalling in normal and pituitary tumour cell growth. Cell cultures were prepared from anterior pituitaries of female Wistar rats and tumour GH3 cells, and treated with 10nM of estradiol (E2). Read More

View Article

Download full-text PDF

Source
https://joe.bioscientifica.com/view/journals/joe/aop/joe-18-
Publisher Site
http://dx.doi.org/10.1530/JOE-18-0418DOI Listing
November 2018
7 Reads

Giant Prolactinoma in Men: Clinical Features and Therapeutic Outcomes.

Horm Metab Res 2018 Nov 5;50(11):791-796. Epub 2018 Nov 5.

Department of Endocrinology, Hospital Universitario Ramón y Cajal, Madrid, Spain.

The aim of the study was to evaluate the clinical features and long-term therapeutic outcome of giant prolactinoma (gPRLoma) in men and to compare them with those of a group of male patients with non-gPRL macroprolactinomas (non-gPRLomas). A retrospective and multicenter study of gPRLomas in men diagnosed in a 20-year period was performed. Clinical data and treatment outcome were registered. Read More

View Article

Download full-text PDF

Source
http://www.thieme-connect.de/DOI/DOI?10.1055/a-0752-0741
Publisher Site
http://dx.doi.org/10.1055/a-0752-0741DOI Listing
November 2018
28 Reads

[Improvement and effect analysis of a new neuroendoscopic trans-nasal-sphenoidal pituitary tumor resection approach].

Zhonghua Yi Xue Za Zhi 2018 Oct;98(37):3021-3024

Department of Neurosurgery, Center of Prolactinoma, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

To modify the individual neuroendoscopic surgical approach of pituitary tumors with specific imaging features, and to analyze the clinical outcomes. The clinical data of 116 patients with pituitary tumors who underwent surgical treatment at the pituitary tumor diagnosis and treatment center of Ruijin Hospital from April 2014 to December 2017 were collected, then the resection effects and complication rates of pituitary tumors from three different kinds of transsphenoidal approaches (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2018.37.015DOI Listing
October 2018
2 Reads